Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A.

The generation of an antibody response capable of neutralizing a broad range of clinical isolates remains an important goal of human immunodeficiency virus type 1 (HIV-1) vaccine development. Envelope glycoprotein (Env)-based vaccine candidates will also need to take into account the extensive genetic diversity of circulating HIV-1 strains. We describe here the generation of soluble, stabilized, proteolytically cleaved, trimeric forms of Env (SOSIP gp140 proteins) based on contemporary Env subtype A viruses from East Africa. We discuss issues associated with the construction, purification, and characterization of such complex proteins; not all env sequences allow the expression of trimeric proteins. However, stabilized trimers from one such protein, KNH1144 SOSIP gp140, were successfully made. These proteins are now being prepared for preclinical immunogenicity studies.

[1]  J. Mascola,et al.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination , 2007, Current opinion in HIV and AIDS.

[2]  John P. Moore,et al.  Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. , 2007, Virology.

[3]  J. Hoxie,et al.  Regulation of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion by a Membrane-Interactive Domain in the gp41 Cytoplasmic Tail , 2005, Journal of Virology.

[4]  J. Sodroski,et al.  The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. , 2005, Virology.

[5]  John P. Moore,et al.  Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). , 2005, Virology.

[6]  William C. Olson,et al.  Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[7]  E. Sanders-Buell,et al.  Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.

[8]  J. Mascola,et al.  Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. , 2005, The Journal of infectious diseases.

[9]  Michael G Hudgens,et al.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.

[10]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[11]  Oliver Hartley,et al.  V3: HIV's switch-hitter. , 2005, AIDS research and human retroviruses.

[12]  R. Wyatt,et al.  Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. , 2005, Virology.

[13]  J. Sodroski,et al.  Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers. , 2005, Virology.

[14]  H. Katinger,et al.  Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1 , 2005, Journal of Virology.

[15]  Bette T. Korber,et al.  Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein , 2005, Journal of Virology.

[16]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[17]  Peter D. Kwong,et al.  Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.

[18]  B. Nahlen,et al.  Genetic diversity and high proportion of intersubtype recombinants among HIV type 1-infected pregnant women in Kisumu, western Kenya. , 2004, AIDS research and human retroviruses.

[19]  M. Feinberg,et al.  Prospects for an AIDS vaccine: three big questions, no easy answers. , 2004, The Lancet. Infectious diseases.

[20]  J. Lineberger,et al.  Coupling of Human Immunodeficiency Virus Type 1 Fusion to Virion Maturation: a Novel Role of the gp41 Cytoplasmic Tail , 2004, Journal of Virology.

[21]  H. Katinger,et al.  The Long Third Complementarity-Determining Region of the Heavy Chain Is Important in the Activity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 , 2004, Journal of Virology.

[22]  B. Moss,et al.  Promoting Trimerization of Soluble Human Immunodeficiency Virus Type 1 (HIV-1) Env through the Use of HIV-1/Simian Immunodeficiency Virus Chimeras , 2004, Journal of Virology.

[23]  R. Desrosiers.  Prospects for an AIDS vaccine , 2004, Nature Medicine.

[24]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[25]  Q. Sattentau,et al.  Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. , 2004, Vaccine.

[26]  E. Freed,et al.  Regulation of Human Immunodeficiency Virus Type 1 Env-Mediated Membrane Fusion by Viral Protease Activity , 2004, Journal of Virology.

[27]  S. A. Gallo,et al.  The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.

[28]  A. McMichael,et al.  HIV vaccines 1983–2003 , 2003, Nature Medicine.

[29]  Yiming Shao,et al.  Enhanced: The Need for a Global HIV Vaccine Enterprise , 2003, Science.

[30]  Paul W. H. I. Parren,et al.  A Novel Human Antibody against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12 , 2003, Journal of Virology.

[31]  J. Sodroski,et al.  Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. , 2003, AIDS research and human retroviruses.

[32]  John P. Moore,et al.  Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.

[33]  S. Yerly,et al.  Travel and the spread of HIV-1 genetic variants. , 2003, The Lancet. Infectious diseases.

[34]  U. Alam,et al.  Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants , 2002, AIDS.

[35]  John P. Moore,et al.  Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.

[36]  D. Montefiori,et al.  Crosslinked HIV-1 envelope–CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Min Lu,et al.  Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein , 2002, Journal of Virology.

[38]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[39]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[40]  D. Montefiori,et al.  Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization , 2002, Journal of Virology.

[41]  J. Sodroski,et al.  Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.

[42]  J. Binley,et al.  Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2002, Journal of Virology.

[43]  L. Stamatatos,et al.  Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus , 2002, Journal of Virology.

[44]  B. Graham.  Clinical trials of HIV vaccines. , 2002, Annual review of medicine.

[45]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[46]  E. Reinherz,et al.  Expression, Purification, and Characterization of Recombinant HIV gp140 , 2001, The Journal of Biological Chemistry.

[47]  Serena Xu,et al.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  John P. Moore,et al.  Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development , 2001, Journal of Virology.

[49]  Joseph Sodroski,et al.  Envelope Glycoprotein Determinants of Neutralization Resistance in a Simian-Human Immunodeficiency Virus (SHIV-HXBc2P 3.2) Derived by Passage in Monkeys , 2001, Journal of Virology.

[50]  D R Burton,et al.  gp120: Biologic aspects of structural features. , 2001, Annual review of immunology.

[51]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[52]  J. Sodroski,et al.  Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.

[53]  G. Learn,et al.  HIV-1 Nomenclature Proposal , 2000, Science.

[54]  J. Binley,et al.  A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.

[55]  D. Richman,et al.  Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy , 2000, AIDS.

[56]  J. Overbaugh,et al.  Gender differences in HIV-1 diversity at time of infection , 2000, Nature Medicine.

[57]  J. Overbaugh,et al.  Variants from the Diverse Virus Population Identified at Seroconversion of a Clade A Human Immunodeficiency Virus Type 1-Infected Woman Have Distinct Biological Properties , 1999, Journal of Virology.

[58]  J. Neilson,et al.  Subtypes of Human Immunodeficiency Virus Type 1 and Disease Stage among Women in Nairobi, Kenya , 1999, Journal of Virology.

[59]  A. Trkola,et al.  Enhancement of Human Immunodeficiency Virus Type 1 Infection by the CC-Chemokine RANTES Is Independent of the Mechanism of Virus-Cell Fusion , 1999, Journal of Virology.

[60]  Q. Sattentau,et al.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.

[61]  A. Trkola,et al.  Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[62]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[63]  J. Bradac,et al.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.

[64]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[65]  T. Greenough,et al.  High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection , 1996, Journal of virology.

[66]  D. Ho,et al.  Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection , 1996, Journal of virology.

[67]  J. Sodroski,et al.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.

[68]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[69]  J. Mascola,et al.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.

[70]  B. Korber,et al.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes , 1996, Journal of virology.

[71]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[72]  J. Sodroski,et al.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.

[73]  Groen,et al.  Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin , 1995, Journal of virology.

[74]  C. Barbas,et al.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.

[75]  J. Moore,et al.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies , 1994, Journal of virology.

[76]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[77]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[78]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[79]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[80]  J. Sodroski,et al.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.

[81]  R. Compans,et al.  The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing. , 1990, Virology.